SG11202108004VA - 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases - Google Patents
2h-indazole derivatives as therapeutic agents for brain cancers and brain metastasesInfo
- Publication number
- SG11202108004VA SG11202108004VA SG11202108004VA SG11202108004VA SG11202108004VA SG 11202108004V A SG11202108004V A SG 11202108004VA SG 11202108004V A SG11202108004V A SG 11202108004VA SG 11202108004V A SG11202108004V A SG 11202108004VA SG 11202108004V A SG11202108004V A SG 11202108004VA
- Authority
- SG
- Singapore
- Prior art keywords
- brain
- therapeutic agents
- indazole derivatives
- cancers
- metastases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798220P | 2019-01-29 | 2019-01-29 | |
| PCT/US2020/015398 WO2020159980A1 (en) | 2019-01-29 | 2020-01-28 | 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108004VA true SG11202108004VA (en) | 2021-08-30 |
Family
ID=71841916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108004VA SG11202108004VA (en) | 2019-01-29 | 2020-01-28 | 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220079944A1 (en) |
| EP (1) | EP3917532A4 (en) |
| JP (1) | JP2022519205A (en) |
| CN (1) | CN113507930A (en) |
| AU (1) | AU2020215684A1 (en) |
| BR (1) | BR112021015004A2 (en) |
| CA (1) | CA3127958A1 (en) |
| CO (1) | CO2021011328A2 (en) |
| EA (1) | EA202191938A1 (en) |
| IL (1) | IL284923A (en) |
| SG (1) | SG11202108004VA (en) |
| TW (1) | TW202042819A (en) |
| WO (1) | WO2020159980A1 (en) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2885B1 (en) * | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| WO2015101293A1 (en) * | 2013-12-31 | 2015-07-09 | 山东轩竹医药科技有限公司 | Kinase inhibitor and use thereof |
| WO2016014904A1 (en) * | 2014-07-24 | 2016-01-28 | Beta Pharma, Inc. | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
| JP6615899B2 (en) * | 2015-02-04 | 2019-12-04 | ビヨンドバイオ インコーポレイテッド | Heterocyclic compound and pharmaceutical composition containing the same |
| ES2806206T3 (en) * | 2015-03-11 | 2021-02-16 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | 2-hydrogen substituted pyrazole derivative that serves as an anticancer drug |
| CN106810536A (en) * | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | A kind of kinases inhibitor and preparation method thereof and medical usage |
| CN107286134B (en) * | 2016-04-11 | 2019-04-12 | 上海勋和医药科技有限公司 | 2,4- disubstituted pyrimidines derivatives are as CDK inhibitor and its application |
| CN109503573A (en) * | 2017-09-14 | 2019-03-22 | 昆明圣加南生物科技有限公司 | 2- substituted anilinic pyrimidine derivatives and application thereof |
| CA3088381A1 (en) * | 2018-01-29 | 2019-08-01 | Beta Pharma, Inc. | 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof |
| US20220162185A1 (en) * | 2019-03-20 | 2022-05-26 | Beta Pharma, Inc. | Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof |
| KR20220004755A (en) * | 2019-05-05 | 2022-01-11 | 치루 레고르 테라퓨틱스 인코포레이티드 | CDK inhibitors |
| CN114430681A (en) * | 2019-09-23 | 2022-05-03 | 贝达医药公司 | Treatment of EGFR mutation-related cancers with combinations of EGFR and CDK4/6 inhibitors |
-
2020
- 2020-01-28 EA EA202191938A patent/EA202191938A1/en unknown
- 2020-01-28 US US17/426,296 patent/US20220079944A1/en active Pending
- 2020-01-28 EP EP20748603.6A patent/EP3917532A4/en active Pending
- 2020-01-28 SG SG11202108004VA patent/SG11202108004VA/en unknown
- 2020-01-28 CA CA3127958A patent/CA3127958A1/en not_active Abandoned
- 2020-01-28 BR BR112021015004-8A patent/BR112021015004A2/en not_active IP Right Cessation
- 2020-01-28 CN CN202080011612.4A patent/CN113507930A/en active Pending
- 2020-01-28 JP JP2021544138A patent/JP2022519205A/en active Pending
- 2020-01-28 AU AU2020215684A patent/AU2020215684A1/en active Pending
- 2020-01-28 WO PCT/US2020/015398 patent/WO2020159980A1/en unknown
- 2020-01-30 TW TW109102914A patent/TW202042819A/en unknown
-
2021
- 2021-07-18 IL IL284923A patent/IL284923A/en unknown
- 2021-08-27 CO CONC2021/0011328A patent/CO2021011328A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220079944A1 (en) | 2022-03-17 |
| IL284923A (en) | 2021-09-30 |
| CO2021011328A2 (en) | 2021-09-20 |
| TW202042819A (en) | 2020-12-01 |
| EA202191938A1 (en) | 2021-10-13 |
| AU2020215684A1 (en) | 2021-08-12 |
| BR112021015004A2 (en) | 2021-10-05 |
| WO2020159980A1 (en) | 2020-08-06 |
| EP3917532A4 (en) | 2022-09-28 |
| CA3127958A1 (en) | 2020-08-06 |
| JP2022519205A (en) | 2022-03-22 |
| CN113507930A (en) | 2021-10-15 |
| EP3917532A1 (en) | 2021-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3781564C0 (en) | Pyridazine derivatives for the treatment of cancer | |
| IL253712A0 (en) | Hemiasterlin derivatives for conjugation and therapy | |
| IL275337A (en) | 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer | |
| SG11202104923YA (en) | Pharmaceutical combination for treatment of cancer | |
| MX2018008427A (en) | Anti-cd20 combinations for treating tumors. | |
| EP3534923A4 (en) | Combination therapy for treatment of brain cancers | |
| IL280337A (en) | Lag-3 combination therapy for the treatment of cancer | |
| IL281927A (en) | Combination therapy for melanoma | |
| IL257670A (en) | Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer | |
| IL282093A (en) | Combination therapy for cancer | |
| PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| IL281845A (en) | Combination therapy for the treatment of cancer | |
| SG11202108636SA (en) | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | |
| IL284162A (en) | Combination therapy for the treatment of cancer | |
| SG11202106295WA (en) | Compositions and methods for cancer therapy | |
| IL263905A (en) | Combination therapy of cancer | |
| IL277875A (en) | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy | |
| EP3449922A4 (en) | Indazole derivatives for cancer treatment | |
| IL270140B (en) | Therapeutic agent for blood cancer | |
| IL284923A (en) | 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases | |
| IL286680A (en) | Medicament for treating cancer | |
| IL286649A (en) | Quinoline derivatives and their use for the treatment of cancer | |
| IL286353A (en) | Combinations of iadademstat for cancer therapy | |
| IL281782A (en) | Pharmaceutical combination for the treatment of cancer | |
| IL268897A (en) | Medicament for malignant tumor treatment |